November 30, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) Final Pricing Determination Medicare Grants Pricing for LungLife’s LungLB® Early Lung Cancer Diagnostic LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Centers for Medicare & Medicaid Services (“CMS”) has granted a price at $2,030 per test for the LungLB® early […]
• Read MoreNovember 30, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) Total Voting Rights The Company’s total issued share capital consists of 25,485,982 Ordinary Shares of US $0.0001 each ("Ordinary Shares") with one voting right per Ordinary Share. There are no Ordinary Shares held in treasury. The total number of voting rights in the Company is therefore 25,485,982. This […]
• Read MoreNovember 15, 2022
15 November 2022 LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Six Monthly Return LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six-monthly update on its block listing: Name of applicant: LungLife AI, Inc. Name of scheme: 2010 Stock Incentive Plan 2020 Stock […]
• Read MoreNovember 7, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) Director share purchases LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that it has received notification of the following transactions in the Company’s common shares of US $0.0001 each (“Common Shares”) undertaken by directors. On 2 November 2022, Paul Pagano, Chief Executive […]
• Read MoreOctober 17, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) LungLife to participate in the US National Cancer Institute’s Early Detection Research Network LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that based on the strength of its technology it will be one of two industry partners to participate in the Boston […]
• Read MoreSeptember 26, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) Half-year Report LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer announces its unaudited half-year report for the six months ended 30 June 2022. Summary and Highlights (including post-period end): Cash as of 30 June 2022 of $10.63m Loss before […]
• Read MoreSeptember 9, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, will announce its interim results for the six months ended 30 June 2022 on Monday 26 September 2022. Investor presentation Paul Pagano, Chief Executive Officer, and David […]
• Read MoreSeptember 2, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) New York State approves LungLB® for commercial testing LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the New York State Department of Health (“NYSDOH”) has awarded LungLife a Clinical Laboratory Evaluation Program (“CLEP”) permit following their recent on-site audit, during […]
• Read MoreMay 16, 2022
16 May 2022 LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Six Monthly Return LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies: Name of […]
• Read More
LungLife AI licensure/accreditation information posted here.